A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers Disease

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Form 46 from DCGI for the manufacturing \& commercial marketing of Stempeucel® directs Stempeutics to conduct PMS study. Hence this study is being terminated.

Conditions

Critical Limb Ischemia Due to Buerger's Disease

Interventions

BIOLOGICAL: Stempeucel(R)

Sponsor

Stempeutics Research Pvt Ltd